Recent Updates
Recently added Catalysts
TVTX Positive Sentiment

Travere Therapeutics Announces Planned Chief Executive Officer Transition

Monday, September 21, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Travere Therapeutics announced the resignation of CEO Eric Dube, who is stepping down to focus on his health and family. The Board of Directors has appointed Bradley L. Campbell, the former CEO of Amicus Therapeutics, as the new president and CEO. This leadership change reflects the company's commitment to continuity and experienced management.

Market Sentiment Analysis

POSITIVE FACTORS

  • Eric Dube's decision is personal and shows prioritization of health.
  • Bradley L. Campbell brings experience as a former CEO.
  • The Board's unanimous decision indicates strong support for the transition.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+68%
120-day peak, hindsight
Typical move
8.6%
average across 10 past catalysts
Lead asset
Sparsentan
Phase 3 · Immunoglobulin A Nephropathy

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company’s Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical Inc., to succeed Dr. Dube as president and chief executive officer and

Frequently Asked Questions

Why did Eric Dube resign as CEO?

Eric Dube resigned to focus on his health and family.

Who is the new CEO of Travere Therapeutics?

Bradley L. Campbell has been appointed as the new CEO.

What experience does Bradley Campbell have?

Bradley Campbell is the former president and CEO of Amicus Therapeutics.

How did the Board react to the CEO transition?

The Board of Directors unanimously supported the appointment of Bradley Campbell.

ShareAdd on Google
Tags: TVTX Viatris Investor Conferences Healthcare Travere Therapeutics Eric Dube Bradley Campbell CEO transition
Last updated: Sep 21, 2026

Biotech snapshot

Cash runway
$489M liquidity · $0M/mo burn
Low dilution risk
Lead asset
SparsentanPhase 3
Immunoglobulin A Nephropathy →

Catalyst track record

+68%
best trade around TVTX's most recent catalyst

Peak hindsight return over a 120-day window, across 10 tracked FDA/PDUFA catalysts for TVTX.

See every catalyst's timing & PoA →